Low-dose rituximab lowers serum Exosomal miR-150-5p in AChR-positive refractory myasthenia gravis patients

被引：16
作者：
Zhong, Huahua [1 ]
Lu, Jun [1 ]
Jing, Sisi [2 ]
Xi, Jianying [1 ]
Yan, Chong [1 ]
Song, Jie [1 ]
Luo, Sushan [1 ]
Zhao, Chongbo [1 ,2 ]
机构：
[1] Fudan Univ, Huashan Hosp, Shanghai Med Coll, Dept Neurol, Shanghai, Peoples R China
[2] Fudan Univ, Jingan Dist Ctr Hosp Shanghai, Dept Neurol, Shanghai, Peoples R China
来源：
JOURNAL OF NEUROIMMUNOLOGY | 2020年 / 348卷
基金：
中国国家自然科学基金;
关键词：
Myasthenia gravis; Rituximab; microRNA; Exosome; MIR-146A; CELLS;
D O I：
10.1016/j.jneuroim.2020.577383
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Two potentially related microRNAs (miRNAs; miR-150-5p and miR-146a-5p) were examined after low-dose rituximab (RTX) treatment in patients with acetylcholine receptor antibody (AChR)-positive refractory myasthenia gravis (MG). In this prospective, open-label, and self-controlled pilot trial, 12 AChR-positive refractory MG patients were administrated a single, low dose of RTX and followed up at six months. Results showed that RTX decreased the serum exosomal miR-150-5p, scores on three clinical indices (MGFA, MMT, ADL), and patients' prednisolone requirement. Additionally, CD19 + and CD27+ B cells decreased, showing a strong correlation with miR-150-5p. In conclusion, low-dose RTX is effective for AChR-positive refractory MG treatment. Furthermore, our data support the role of miR-150-5p as a potential biomarker for MG.
引用
收藏
页数：6
相关论文
共 29 条
  • [1] Rituximab in refractory myasthenia gravis: a prospective, open-label study with long-term follow-up
    Anderson, Dustin
    Phan, Cecile
    Johnston, Wendy S.
    Siddiqi, Zaeem A.
    [J]. ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2016, 3 (07): : 552 - 555
  • [2] MiR-146a levels in rheumatoid arthritis and their correlation with disease activity: a meta-analysis
    Bae, Sang-Cheol
    Lee, Young H.
    [J]. INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2018, 21 (07) : 1335 - 1342
  • [3] Rituximab in refractory myasthenia gravis: Extended prospective study results
    Beecher, Grayson
    Anderson, Dustin
    Siddiqi, Zaeem A.
    [J]. MUSCLE & NERVE, 2018, 58 (03) : 452 - 455
  • [4] Causes and Consequences of miR-150-5p Dysregulation in Myasthenia Gravis
    Cron, Melanie A.
    Maillard, Solene
    Truffault, Frederique
    Gualeni, Ambra Vittoria
    Gloghini, Annunziata
    Fadel, Elie
    Guihaire, Julien
    Behin, Anthony
    Berrih-Aknin, Sonia
    Le Panse, Rozen
    [J]. FRONTIERS IN IMMUNOLOGY, 2019, 10
  • [5] Immunotherapy in myasthenia gravis in the era of biologics
    Dalakas, Marinos C.
    [J]. NATURE REVIEWS NEUROLOGY, 2019, 15 (02) : 113 - 124
  • [6] Rituximab in AChR subtype of myasthenia gravis: systematic review
    Di Stefano, Vincenzo
    Lupica, Antonino
    Rispoli, Marianna Gabriella
    Di Muzio, Antonio
    Brighina, Filippo
    Rodolico, Carmelo
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2020, 91 (04) : 392 - 395
  • [7] c-Myb Is Required for Pro-B Cell Differentiation
    Fahl, Shawn P.
    Crittenden, Rowena B.
    Allman, David
    Bender, Timothy P.
    [J]. JOURNAL OF IMMUNOLOGY, 2009, 183 (09) : 5582 - 5592
  • [8] Myasthenia gravis
    Gilhus, Nils Erik
    Tzartos, Socrates
    Evoli, Amelia
    Palaces, Jacqueline
    Burns, Ted M.
    Verschuuren, Jan J. G. M.
    [J]. NATURE REVIEWS DISEASE PRIMERS, 2019, 5
  • [9] Myasthenia gravis: subgroup classification and therapeutic strategies
    Gilhus, Nils Erik
    Verschuuren, Jan J.
    [J]. LANCET NEUROLOGY, 2015, 14 (10) : 1023 - 1036
  • [10] MicroRNA-150: A potential regulator in pathogens infection and autoimmune diseases
    Huang, Xiao-Lei
    Zhang, Li
    Li, Jian-Ping
    Wang, Yu-Jie
    Duan, Yu
    Wang, Jing
    [J]. AUTOIMMUNITY, 2015, 48 (08) : 503 - 510
123